Marwa Refaie | Medicine and Health Sciences | Pioneer Researcher Award

Posted on by Forensic Scientist

Assist. Prof. Dr. Marwa Refaie | Medicine and Health Sciences | Pioneer Researcher Award

Minya University | Egypt

Dr. Marwa Monier Mahmoud Refaie is an esteemed Egyptian pharmacologist and academician currently serving as an Assistant Professor in the Department of Pharmacology, Faculty of Medicine, Minia University. With an H-index of 18 on both Scopus and Google Scholar, she has made impactful contributions to pharmacological research, particularly in drug safety, toxicology, and disease treatment models. Born on July 2, 1983, in Mallawi, El-Minia, Dr. Refaie balances her thriving career with family life, being a proud mother of three sons.

Professional profileđŸ‘€

Google Scholar

Scopus

ORCID

Strengths for the Awards✹

Dr. Marwa Monier Mahmoud Refaie demonstrates a remarkable profile that aligns seamlessly with the ethos of the Pioneer Researcher Award. With over 16 years of academic and research experience in pharmacology, she has established herself as a thought leader in experimental and clinical pharmacology, especially in toxicology, nephroprotection, cardioprotection, and hormonal therapy research.

Her impressive H-index of 18 (Scopus & Google Scholar) reflects the consistent impact of her work on the scientific community. Dr. Refaie has authored over 40 international publications, many in high-impact journals, and has investigated novel therapeutic mechanisms for critical conditions like nephrotoxicity, PCOS, and ischemia-reperfusion injuries. Her robust experimental skill set, prolific mentorship of postgraduate students, and service on editorial boards of globally recognized journals (e.g., British Journal of Pharmacology, Elsevier journals) reflect both leadership and innovation in her field. Moreover, her multiple awards from Minia University for international publication over consecutive years affirm her consistency and excellence in pioneering pharmacological research.

🎓 Education

Dr. Refaie began her academic journey at Minia University, earning her MBBS in Medicine and Surgery in 2006. She further specialized in pharmacology, completing her Master’s in 2011 and a Ph.D. in Basic and Clinical Pharmacology in 2016. Expanding her interdisciplinary expertise, she also earned a Diploma in Infection Control in 2021, highlighting her dedication to integrated healthcare education and safety.

đŸ§Ș Experience

With over 16 years of academic and research experience, Dr. Refaie has evolved from a Demonstrator to Assistant Professor at Minia University. Her work spans teaching basic and clinical pharmacology to medical, dental, pharmacy, and nursing students, and supervising numerous M.Sc. and Ph.D. theses. Her research explores pharmacotherapy, cancer, autoimmune diseases, and drug safety, and she has actively contributed to institutional accreditation, infection control, and community healthcare education.

🔬 Research Interests On Medicine and Health Sciences

Dr. Refaie’s research is driven by a passion for understanding and combating toxicological and precancerous conditions. Her focus lies in modeling and treating organ-specific toxicity, ischemia-reperfusion injuries, and hyperplastic lesions. Her work also explores novel mechanisms of cardioprotection, reproductive toxicity, and immunomodulation using pharmacological agents such as diacerein, fenofibrate, and SGLT2 inhibitors.

🏆 Awards

Dr. Refaie has received consistent recognition for her excellence in research and publication. She was awarded first place at the 57th Annual Conference of the Egyptian Society of Pharmacology and Experimental Therapeutics (2018). Additionally, she has received Minia University’s International Publication Award for six consecutive years (2019–2024), reflecting her sustained contributions to global pharmacological science.

📚 Publications

  • Effect of coenzyme‐Q10 on doxorubicin‐induced nephrotoxicity in rats
    AAK El-Sheikh, MA Morsy, MM Mahmoud, RA Rifaai, AM Abdelrahman
    2012 – Cited by: 147

  • Possible protective effect of diacerein on doxorubicin‐induced nephrotoxicity in rats
    MMM Refaie, EF Amin, NF El-Tahawy, AM Abdelrahman
    2016 – Cited by: 96

  • Mechanism mediating the protective effect of diacerein in ischemia-reperfusion-induced testicular injury in rats
    SA Abdel-Gaber, RK Mohammed, MMM Refaie
    2018 – Cited by: 62

  • Protective mechanisms of coenzyme-Q10 may involve up-regulation of testicular P-glycoprotein in doxorubicin-induced toxicity
    AAK El-Sheikh, MA Morsy, MM Mahmoud, RA Rifaai
    2014 – Cited by: 52

  • Naringenin palliates cisplatin and doxorubicin gonadal toxicity in male rats
    AA Fouad, MMM Refaie, MI Abdelghany
    2019 – Cited by: 50

  • The role of interleukin‐1ÎČ and its antagonist (diacerein) in estradiol benzoate‐induced endometrial hyperplasia and atypia in female rats
    MMM Refaie, M El‐Hussieny
    2017 – Cited by: 48

  • Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity
    MMM Refaie, S Shehata, M El-Hussieny, WM Abdelraheem, …
    2020 – Cited by: 46

  • Assessment of Antibacterial and Anti-biofilm Effects of Vitamin C Against Pseudomonas aeruginosa Clinical Isolates
    WM Abdelraheem, MMM Refaie, RKM Yousef, AS Abd El Fatah, …
    2022 – Cited by: 44

  • Protective role of nebivolol in cadmium-induced hepatotoxicity via downregulation of oxidative stress, apoptosis and inflammatory pathways
    MMM Refaie, M El-Hussieny, NM Zenhom
    2018 – Cited by: 43

  • Protective effect of pioglitazone on ovarian ischemia reperfusion injury of female rats via modulation of peroxisome proliferator activated receptor gamma and heme-oxygenase 1
    MMM Refaie, M El-Hussieny
    2018 – Cited by: 41

📝 Conclusion

🌟 Dr. Marwa M. Refaie exemplifies excellence in academic pharmacology through her sustained research, impactful publications, and commitment to medical education. Her work spans cutting-edge experimental pharmacology, disease modeling, and immunotherapy. Her consistent accolades, active international collaborations, and editorial contributions to top journals affirm her candidacy as a distinguished nominee for prestigious research awards. Her legacy in pharmacological sciences continues to inspire and uplift the global scientific community.

 

Sivahari Gorantla | Health Sciences | Best Researcher Award

Posted on by Forensic Scientist

Dr. Sivahari Gorantla | Health Sciences | Best Researcher Award

Dept Of Hematology And Oncology | Germany

Dr. Sivahari Prasad Gorantla, born on July 25, 1980, in India, is a Junior Group Leader at the Signal Transduction Lab at the University Medical Center, UniversitĂ€tsklinikum Schleswig-Holstein, Campus LĂŒbeck. His research focuses on molecular therapeutics, targeted therapy, and drug resistance mechanisms. He is recognized for his groundbreaking work in the development of therapies targeting JAK2 and other kinases in myeloproliferative neoplasms.

Professional profileđŸ‘€

Google Scholar

ORCID

Scopus

Strengths for the Awards✹

  • Extensive Research Experience: Dr. Gorantla’s research spans a wide range of significant areas, including molecular therapeutics, cancer research, and drug resistance mechanisms, making him a key contributor to advancements in these fields.

  • Outstanding Publication Record: His research publications in high-impact journals such as Nature Communications, Leukemia, and Molecular Oncology highlight his ability to generate novel and impactful insights in his field.

  • International Recognition and Honors: Dr. Gorantla has received multiple awards, including the “Young Investigator Prize” from DGHO and the “Abstract Achievement Award” from the American Association of Hematology. His recognition by prestigious organizations indicates his high standing in the scientific community.

  • Successful Grant Acquisition: His ability to secure substantial research grants from prestigious sources (e.g., DAAD, DFG, Wegener Foundation) is a testament to his research credibility and the relevance of his work.

  • Teaching and Mentoring: His involvement in teaching medical students and master’s students, particularly in the areas of molecular life sciences and genomics, showcases his dedication to education and mentoring the next generation of researchers.

Education 🎓

Dr. Gorantla completed his Ph.D. in Hematology and Oncology from Klinikum rechts der Isar, TUM in 2010. He then pursued multiple postdoctoral fellowships, including at the University Clinic Freiburg and the prestigious Hematology and Oncology department at TUM. His academic journey also includes a Master’s in Biotechnology from the University of Calicut.

Experience đŸ’Œ

Dr. Gorantla’s career spans several key positions, including Assistant Professor at the University of Hyderabad, India, and Independent Postdoctoral Fellow at University Clinic Freiburg. His work involves leading research in molecular mechanisms behind cancer resistance to therapy and the development of novel therapeutic strategies. He currently holds his position as Junior Group Leader at the University Medical Center LĂŒbeck.

Research Interests On Health Sciences 🔬

Dr. Gorantla’s research revolves around molecular therapeutics, targeted therapy, and mechanisms of drug resistance, particularly in blood cancers like leukemia and myeloproliferative neoplasms. He has contributed to understanding the role of JAK2 and other kinases in resistance to treatment, paving the way for novel treatment strategies.

Awards 🏆

Throughout his career, Dr. Gorantla has earned several prestigious accolades. Notable among them are the Young Investigator Prize by DGHO (German Hematology Association) in 2010 and the Abstract Achievement Award from the American Association of Hematology in 2013. He has also been a finalist for the AACR Scholar-in-Training Award and won multiple travel awards at major hematology conferences.

Publications 📚

Dr. Gorantla has authored numerous impactful publications in the field of oncology. Some of his significant works include:

  • Gorantla SP, Rassner M, et al. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is mediated mainly by targeting pro-inflammatory cytokine signaling not oncogenic signaling (Accepted in Nature Communications, 2024). Nature Communications

  • Gorantla SP, Oelschlager L, et al. Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation (Accepted in Leukemia, 2024). Leukemia Journal

  • Gorantla SP, Mueller TA, et al. A newly identified 45-kDa JAK2 variant (Mol Oncol, 2024). Mol Oncol
    His work is widely cited in the field, with articles being referenced by researchers and clinicians worldwide.

Conclusion 🌍

Dr. Sivahari Prasad Gorantla has emerged as a leader in the field of molecular oncology, particularly in the development of targeted therapies for blood cancers. His dedication to research, extensive experience, and numerous accolades make him a valuable contributor to scientific advancements in cancer treatment. With ongoing research grants and fellowships, Dr. Gorantla continues to push the boundaries of medical science, offering new hope for cancer patients worldwide.

Katia Collomp | Health Sciences | Women Researcher Award

Posted on by Forensic Scientist

Prof. Dr. Katia Collomp | Health Sciences | Women Researcher Award

Professor, Orleans University | France

Professor Catherine (Katia) Collomp is a distinguished academic in Sport Sciences at the University of Orleans, France, and a Research Fellow at the French Antidoping Laboratory (LADF), University of Paris-Saclay. With an exceptional career dedicated to the intersection of pharmacology, exercise physiology, and anti-doping science, she is also a key member of the CIAMS laboratory. Her work has significantly influenced anti-doping policies and research ethics in sports science, making her a leading voice in the field.

Professional profileđŸ‘€

ORCID

Scopus

Strengths for the Awards✹

  • Extensive Experience & Leadership
    Professor Collomp has over three decades of continuous and impactful contributions to sport sciences, pharmacology, and anti-doping research. Her role as a full professor and long-term research fellow at the French Antidoping Laboratory (LADF) demonstrates academic excellence and institutional commitment.

  • Interdisciplinary Expertise
    Her background as a pharmacist and researcher in physical activity and health sciences reflects a rare interdisciplinary blend that strengthens both the scientific rigor and practical impact of her work, especially in anti-doping studies—a field requiring deep knowledge of pharmacology, ethics, and sports physiology.

  • Global and National Collaborations
    Her postdoctoral research in Canada and continued collaborations with major institutions like University of Paris-Saclay and WADA position her as an internationally connected researcher. These connections indicate a high level of respect and trust in her expertise.

  • Institutional Service & Policy Impact
    Professor Collomp has held numerous leadership and advisory roles:

    • Co-director of the CIAMS lab team

    • Expert reviewer for HCERES

    • Member of ethics committees and national academic councils (CNU

🎓 Education

Katia Collomp began her academic journey by earning her degree in Pharmacy from the University of Montpellier I in 1987. She went on to complete her Ph.D. in 1991, focusing on “Physical activity, psychological and motor development” within the Life Sciences and Health section at the same university. 📘 Following her doctorate, she undertook a postdoctoral fellowship from 1992 to 1993 at the INRS SantĂ© Antidoping Laboratory in MontrĂ©al, deepening her expertise in doping control and bioanalysis. She achieved her Habilitation Ă  Diriger des Recherches (HDR) in 1997, establishing her as a senior scientific leader in her field.

đŸ’Œ Experience

From 1993 to 1997, Katia served as a Pharmacist at the Mission Sports Medicine – Doping Control, Ministry of Sports in Paris, contributing to the foundation of anti-doping protocols. In 1997, she joined the French Antidoping Laboratory (LADF) as a Research Fellow, a position she continues to hold. Her academic path includes positions as Associate Professor (1997–2001) at the University of Paris XI and Full Professor (2001–present) at the University of Orleans. She has led multiple research teams and contributed to national committees on education and ethics.

🔬 Research Interest On Health Sciences

Her research interests span pharmacology, performance-enhancing substances, glucocorticoids, sports physiology, and rehabilitation. She focuses on the effects of physical activity on health and doping control, contributing to ethical frameworks and scientific methodologies that guide international sports policies. Her work helps shape understanding of how substances influence athletic performance and rehabilitation, playing a crucial role in global anti-doping efforts.

🏅 Awards & Honors

Professor Collomp has served in multiple national and international scientific committees, including as an expert for HCERES, a member of the WADA Glucocorticoids Threshold Working Group, and the Research Ethics Committee of Paris-Saclay (CER). She is currently a member of the French “Conseil National des UniversitĂ©s” (CNU 74), reflecting her respected status in the academic and sports science community. đŸŽ–ïž Her leadership and advocacy for scientific integrity in sports continue to influence generations of researchers and athletes alike.

📚 Publications

1. Hormonal and Metabolic Responses Across Phases of Combined Oral Contraceptive Use and Menstrual Cycle in Young Elite Female Athletes

  • Authors: Katia Collomp, AgnĂšs Olivier, Caroline Teulier, Juliette Bonnigal, Nathalie CrĂ©pin, Corinne Buisson, Magnus Ericsson, Emmanuelle Duron, Eric Favory, Mathieu Zimmermann, et al.

  • Year: 2025

  • Journal: European Journal of Applied Physiology

  • DOI: 10.1007/s00421-025-05745-x

2. Impact of Menstrual Cycle and Oral Contraceptives on Haematological and Inflammatory Biomarkers in Highly Trained Female Athletes

  • Authors: Katia Collomp, Caroline Teulier, Carole Castanier, Juliette Bonnigal, Alexandre Marchand, Corinne Buisson, Magnus Ericsson, Nathalie CrĂ©pin, Emmanuelle Duron, Eric Favory, et al.

  • Year: 2025

  • Journal: Drug Testing and Analysis

  • DOI: 10.1002/dta.3859

3. Correlation Between Serum and Saliva Sex Hormones in Young Female Athletes

  • Authors: Katia Collomp, AgnĂšs Olivier, Carole Castanier, Juliette Bonnigal, ValĂ©rie Bougault, Corinne Buisson, Magnus Ericsson, Emmanuelle Duron, Eric Favory, Mathieu Zimmermann, et al.

  • Year: 2025

  • Journal: The Journal of Sports Medicine and Physical Fitness

  • DOI: 10.23736/s0022-4707.24.16488-2

4. Editorial: Women in Sports 2022

  • Authors: Katia Collomp, S. Lorenzetti

  • Year: 2024

  • Journal: Frontiers in Physiology

  • DOI: 10.3389/fphys.2024.1367605

5. Physical Activity and Female Students’ Perception of Menstrual Symptoms: Impact of Hormonal Contraception

  • Authors: Katia Collomp, Sandrine Schiano-Lomoriello, Carole Castanier, Corinne Buisson, Magnus Ericsson, Caroline Teulier, ValĂ©rie Bougault

  • Year: 2024

  • Conference Paper: HAL: hal-04936867

  • Citations: 0​

6. Correlation Between Serum and Saliva Sex Hormones in Young Female Athletes

  • Authors: Katia Collomp, AgnĂšs Olivier, Carole Castanier, Caroline Teulier, Juliette Bonnigal, ValĂ©rie Bougault, Corinne Buisson, Magnus Ericsson, Emmanuelle Duron, Eric Favory, et al.

  • Year: 2024

  • Conference Paper: HAL: hal-04936872

7. Physical Activity and Combined Hormonal Contraception: Association with Female Students’ Perception of Menstrual Symptoms

  • Authors: ValĂ©rie Bougault, Sandrine Schiano-Lomoriello, Carole Castanier, Corinne Buisson, Magnus Ericsson, Caroline Teulier, Katia Collomp

  • Year: 2023

  • Journal: Frontiers in Physiology

  • DOI: 10.3389/fphys.2023.1185343

8. Short-Term Effect of Bariatric Surgery on Cardiorespiratory Response at Submaximal, Ventilatory Threshold, and Maximal Exercise in Women with Severe Obesity

  • Authors: Nancy Vibarel-Rebot, Marine Asselin, Virgile Amiot, Katia Collomp

  • Year: 2023

  • Journal: Obesity Surgery

  • DOI: 10.1007/s11695-023-06550-1

9. Summer Olympic Sports and Female Athletes: Comparison of Anti-Doping Collections and Prohibited Substances Detected in Australia and New Zealand vs. France

  • Authors: Corinne Buisson, L. Brooker, C. Goebel, R. Morrow, R. Chakrabarty, N. Speers, A. Molina, Magnus Ericsson, Katia Collomp

  • Year: 2023

  • Journal: Frontiers in Sports and Active Living

  • DOI: 10.3389/fspor.2023.1213735

10. Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences

  • Authors: Katia Collomp, Magnus Ericsson, N. Bernier, Corinne Buisson

  • Year: 2022

  • Journal: Frontiers in Sports and Active Living

  • DOI: 10.3389/fspor.2022.839976

🔚 Conclusion

Professor Catherine Collomp exemplifies the union of scientific excellence, ethical integrity, and academic leadership in the field of sport sciences and pharmacology. Her dedication to clean sport, athlete health, and rigorous scientific inquiry continues to guide anti-doping practices across the globe. Her nomination for any award would reflect her lifelong commitment to advancing science in service of both health and fairness in athletics.